<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute caffeine poisoning</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute caffeine poisoning</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acute caffeine poisoning</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adrienne R Hughes, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert G Hendrickson, MD, FACMT, FAACT</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 22, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3815503170"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Caffeine is a widely consumed, plant-derived methylxanthine alkaloid and psychostimulant. Caffeine is found in coffee, tea, chocolate, carbonated sodas, energy drinks, various foods, and powder and tablet forms (including dietary supplements). Although relatively uncommon, fatal poisoning can occur after a large caffeine overdose. Caffeine poisoning remains an ongoing problem given the widespread availability of concentrated caffeine products.</p><p>This topic will review the clinical features, evaluation, and management of acute caffeine poisoning in children and adults. The general management of the poisoned patient, effects of chronic caffeine use, and high-risk dietary supplements are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/13850.html" rel="external">"Initial management of the critically ill adult with an unknown overdose"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1553.html" rel="external">"Cardiovascular effects of caffeine and caffeinated beverages"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5369.html" rel="external">"Benefits and risks of caffeine and caffeinated beverages"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/406.html" rel="external">"Caffeine: Effects on reproductive outcomes in females"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/126971.html" rel="external">"High-risk dietary supplements: Patient evaluation and counseling"</a>.)</p><p></p><p class="headingAnchor" id="H2079095517"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Severe and lethal caffeine poisoning tends to involve the ingestion of concentrated caffeine products (eg, caffeine-containing medications or pure anhydrous caffeine powder) rather than beverages or foods containing caffeine [<a href="#rid1">1-3</a>]<em>. </em>Approximately 3000 single-substance caffeine exposures involving two or fewer fatalities are reported annually to United States regional poison control centers [<a href="#rid4">4-7</a>]. Approximately 1000 energy drink exposures are reported annually to United States regional poison control centers (with one fatality reported between 2017 and 2020).</p><p>Cases of intentional and unintentional caffeine poisoning in the United States have increased since the widespread use of caffeine-enhanced items (eg, energy drinks) and highly concentrated caffeine products [<a href="#rid8">8-10</a>]. Excess consumption of energy drinks can cause severe toxicity; these make up a small percentage of the overall consumed caffeine, but their consumption appears to be increasing [<a href="#rid10">10-14</a>]<em>.</em> In 2014, the US Food and Drug Administration warned consumers about dietary supplements containing pure or highly concentrated caffeine and the potential for dangerous and serious adverse events [<a href="#rid15">15</a>]<em>.</em></p><p class="headingAnchor" id="H1716002426"><span class="h1">PHARMACOLOGY AND CELLULAR TOXICOLOGY</span></p><p class="headingAnchor" id="H1334564799"><span class="h2">Sources and toxic dose</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sources</strong> — Caffeine is a common component of various beverages, energy drinks, and chocolates  (<a class="graphic graphic_table graphicRef79304" href="/d/graphic/79304.html" rel="external">table 1</a>). In the United States, the majority of consumed caffeine is from beverages such as coffee, tea, and soft drinks [<a href="#rid14">14</a>]<em>. </em>Caffeine occurs naturally in a wide variety of seeds, nuts, and plant species. Caffeine is present in many over-the-counter (OTC) weight-loss and pre-workout supplements  (<a class="graphic graphic_table graphicRef139130" href="/d/graphic/139130.html" rel="external">table 2</a>), combination analgesics (eg, Excedrin Extra Strength), and concentrated powders and liquids. Almost pure caffeine powder containing up to 5 grams caffeine per teaspoon is available for bulk purchase on the internet. Caffeine is also a common adulterant in illicit stimulants sold by internet vendors [<a href="#rid16">16</a>]<em>.</em></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxic dose</strong> —<strong> </strong>Ingestion of greater than 150 to 200 mg/kg of caffeine has a high risk of lethality. In general, intentional ingestion (ie, overdose) is the most dangerous form of exposure since it often involves very high doses of caffeine. Fatalities have been reported with the ingestion of 5 to 50 g, but recovery after ingestion of up to 50 g has also been described [<a href="#rid17">17-19</a>]<em>.</em> In a study of 101 patients hospitalized for caffeine poisoning, the mean dose of caffeine ingested was 7.2 g (range of 1.2 to 82.6 g) [<a href="#rid20">20</a>]<em>.</em> Seven of these hospitalized patients had a cardiac arrest (all consumed ≥6 g), and three patients died.</p><p></p><p class="bulletIndent1">In most adults, consumption of up to 400 mg per day of caffeine appears to be s<em>af</em>e<em>. </em>In children and adolescents, consumption of 2.5 mg/kg per day is not associated with adverse effects. The amount of caffeine consumed in beverages and other forms is discussed separately.<em> </em>(See  <a class="medical medical_review" href="/d/html/5369.html" rel="external">"Benefits and risks of caffeine and caffeinated beverages", section on 'Consumption'</a>.)</p><p></p><p class="headingAnchor" id="H1062831738"><span class="h2">Therapeutic and toxic serum concentrations</span><span class="headingEndMark"> — </span>When used for treatment of apnea of prematurity, the therapeutic range of caffeine concentrations is 8 to 20 mg/L (44 to 111 mmol/L).</p><p>The range of toxic caffeine concentrations reported in the literature varies greatly [<a href="#rid21">21</a>]. In general, concentrations &gt;20 mg/L (111 mmol/L) are potentially toxic, and concentrations &gt;50 mg/L (278 mmol/L) are consistently toxic.</p><p>Concentrations &gt;80 mg/L (444 mmol/L) are associated with fatality, but survival after acute caffeine overdose has been reported with much higher serum concentrations [<a href="#rid2">2,21,22</a>]<em>. </em>In a study of 51 caffeine-related fatalities, the mean postmortem concentration was 187 mg/L (1038 mmol/L), and the range was 33 to 567 mg/L (183 to 3147 mmol/L) [<a href="#rid23">23</a>]<em>.</em></p><p class="headingAnchor" id="H2111005534"><span class="h2">Pharmacology and mechanisms of toxicity</span><span class="headingEndMark"> — </span>Caffeine is a trimethylxanthine, a structural analog of adenosine and the dimethylxanthines (ie, <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a>, theobromine). Compared with the dimethylxanthines, caffeine's extra methyl group increases central nervous system (CNS) penetration. The physiologic effects of caffeine are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1553.html" rel="external">"Cardiovascular effects of caffeine and caffeinated beverages", section on 'Physiologic effects'</a>.)</p><p>Caffeine is a nonselective adenosine receptor antagonist. Presynaptic adenosine-2 receptor antagonism promotes catecholamine (eg, norepinephrine) release, resulting in increased myocardial inotropy and chronotropy, peripheral vasoconstriction, and indirect excitatory effects [<a href="#rid24">24</a>]<em>.</em> At recommended doses, caffeine acts as a mild CNS stimulant, but in overdose, seizures can develop from antagonism of CNS adenosine receptors [<a href="#rid3">3</a>]<em>.</em></p><p>Caffeine stimulates the CNS respiratory center and is used therapeutically to treat apnea of prematurity [<a href="#rid25">25,26</a>]. (See  <a class="medical medical_review" href="/d/html/5048.html" rel="external">"Management of apnea of prematurity", section on 'Caffeine'</a>.)</p><p>At high concentrations, caffeine inhibits phosphodiesterase, thus increasing cyclic adenosine monophosphate (cAMP) and intracellular calcium concentrations [<a href="#rid27">27</a>]<em>. </em>Increased cAMP, which is part of the postsynaptic beta-adrenergic second messenger system, results in the beta-adrenergic effects of smooth muscle relaxation, peripheral vasodilation, increased myocardial inotropy and chronotropy, skeletal muscle contractility, and CNS excitation. (See  <a class="medical medical_review" href="/d/html/3451.html" rel="external">"Excitation-contraction coupling in myocardium", section on 'Cyclic adenosine monophosphate'</a>.)</p><p class="headingAnchor" id="H206769886"><span class="h2">Pharmacokinetics</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Absorption </strong>– Caffeine is rapidly absorbed from the stomach and small intestine with 90 to 100 percent bioavailability [<a href="#rid24">24,28</a>]<em>.</em> Peak caffeine concentrations occur 30 to 60 minutes after oral intake [<a href="#rid24">24,29</a>]<em>. </em>Food slows the rate of absorption but does not limit the extent [<a href="#rid30">30</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Distribution</strong> – Caffeine distributes into the total body water compartment and has a volume of distribution of approximately 0.7 L/kg, and 10 to 35 percent is bound to plasma protein [<a href="#rid31">31,32</a>]<em>.</em> Caffeine crosses the placenta and passes into breast milk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism</strong> – Caffeine is hepatically metabolized via cytochrome P450 (CYP1A2) into paraxanthine (1,7-dimethylxanthine; major metabolite), theobromine, and <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> (minor metabolites) [<a href="#rid33">33</a>]<em>.</em> Paraxanthine is further metabolized to the principal urinary metabolites, 1-methylxanthine, 1-methyluric acid, and an acetylated uracil derivative. Caffeine biotransformation manifests significant inter-individual variability [<a href="#rid34">34</a>]<em>.</em> For example, individuals homozygous for the CYP1A2*1A allele are rapid metabolizers of caffeine, while carriers of the CYP1A2*1F allele are slow metabolizers [<a href="#rid35">35</a>]. In a study of healthy volunteers, lower CYP1A2 activity was associated with increased reports of symptoms of toxicity [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elimination</strong> – The mean plasma elimination half-life is approximately five hours (range three to seven hours) in healthy adults and shorter in children (three to four hours). The half-life is shortened in smokers and prolonged in the last trimester of pregnancy, patients with cirrhosis, and infants. Less than 5 percent of caffeine is excreted unchanged in the urine. Caffeine obeys first-order kinetics, but zero-order kinetics occur at supratherapeutic concentrations because of saturation of metabolic enzymes [<a href="#rid37">37</a>]. There is marked interindividual variation in the rate of elimination.</p><p></p><p class="headingAnchor" id="H213163050"><span class="h1">CLINICAL FEATURES OF OVERDOSE</span></p><p class="headingAnchor" id="H3438001151"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Caffeine toxicity can present with a range of gastrointestinal, cardiovascular, metabolic, muscular, and central nervous system (CNS) effects<em>.</em> The characteristic caffeine poisoning syndrome (ie, toxidrome) is the combination of vomiting, tachycardia, hypokalemia, and hyperglycemia. Toxicity is generally dose dependent, and at higher doses, agitation, seizures, ventricular dysrhythmias, hypotension, and shock can occur [<a href="#rid8">8,38-41</a>].</p><p>A study of 101 patients hospitalized for caffeine toxicity (most from caffeine tablet overdose) found that commonly reported symptoms and signs included [<a href="#rid20">20</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypokalemia: 85 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Nausea: 81 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Vomiting: 74 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Tachycardia: 59 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Tachypnea: 57 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperglycemia: 47 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Depressed consciousness: 37 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperlactatemia: 34 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Agitation or excitement: 27 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Headache: 14 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Irritability: 10 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Tremulousness: 8 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Hypotension: 7 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac arrest: 7 percent</p><p></p><p>The caffeine poisoning toxidrome is essentially equivalent to the beta-adrenergic agonist poisoning toxidrome, which occurs with toxicity from <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a>, <a class="drug drug_general" data-topicid="9396" href="/d/drug information/9396.html" rel="external">albuterol</a>, clenbuterol, and others  (<a class="graphic graphic_table graphicRef51200" href="/d/graphic/51200.html" rel="external">table 3</a>). The preferential beta-adrenergic stimulation due to phosphodiesterase inhibition by caffeine accounts for the clinical overlap with beta-adrenergic agonists (eg, albuterol). (See <a class="local">'Pharmacology and mechanisms of toxicity'</a> above.)</p><p>A rapid overview table provides the common clinical findings after caffeine poisoning  (<a class="graphic graphic_table graphicRef140994" href="/d/graphic/140994.html" rel="external">table 4</a>).</p><p class="headingAnchor" id="H372503593"><span class="h2">Vomiting and other gastrointestinal symptoms</span><span class="headingEndMark"> — </span>Gastrointestinal symptoms such as nausea, vomiting, abdominal pain, and diarrhea are frequently reported after acute caffeine overdose. In large overdoses, vomiting may be severe, recurrent, and difficult to control [<a href="#rid42">42</a>]<em>.</em></p><p class="headingAnchor" id="H3377254331"><span class="h2">Tachycardia and other cardiovascular signs</span><span class="headingEndMark"> — </span>Cardiovascular findings include hypertension (early or mild toxicity), hypotension (severe or late toxicity), tachycardia, ventricular extrasystoles, myocardial ischemia, atrioventricular block, supraventricular tachycardia, ventricular tachycardia, ventricular fibrillation, and cardiac arrest.</p><p>Sinus tachycardia occurs in almost every patient with caffeine toxicity but can degenerate to a more dangerous dysrhythmia. Other tachydysrhythmias (eg, atrial fibrillation) are common in patients with acute caffeine toxicity and are frequently supraventricular in origin [<a href="#rid21">21,43,44</a>]. Ventricular tachycardia or fibrillation occurs with severe toxicity and is typically the proximate cause of death.</p><p>Hypertension can occur with mild toxicity or early in the course of severe toxicity from stimulation of post-synaptic alpha-1 adrenergic receptors. As toxicity progresses, hypotension may develop from beta-2-adrenergic-induced vasodilation, reduced cardiac filling and output from recurrent dysrhythmias, and volume loss from vomiting.</p><p>Other reported cardiovascular effects include fluctuations in T-wave morphology [<a href="#rid44">44</a>], QTc interval prolongation [<a href="#rid44">44,45</a>]<em>,</em> myocardial ischemia and infarction [<a href="#rid46">46</a>]<em>,</em> and cardiac arrest [<a href="#rid41">41,45</a>]<em>.</em></p><p class="headingAnchor" id="H2559734157"><span class="h2">Tachypnea and respiratory failure</span><span class="headingEndMark"> — </span>Tachypnea and respiratory alkalosis can occur. Severe overdose can cause hyperventilation, respiratory alkalosis, respiratory failure, respiratory arrest, and acute respiratory distress syndrome.</p><p class="headingAnchor" id="H1215471326"><span class="h2">Hypokalemia, hyperglycemia, and other metabolic findings</span><span class="headingEndMark"> — </span>Hypokalemia and hyperglycemia occur in most patients with caffeine toxicity. Other metabolic findings after acute caffeine overdose can include leukocytosis, hyponatremia, hypocalcemia, hyperlactatemia, metabolic acidosis, diuresis, and hyperthermia.</p><p>Increased catecholamine release and beta-2-agrenergic agonism are responsible for the hypokalemia, hyperglycemia, and leukocytosis. Potassium is shifted intracellularly, while total body potassium stores are unchanged. Several studies have found that the extent of hypokalemia correlates with the severity of caffeine toxicity [<a href="#rid47">47-49</a>]<em>.</em> Serum glucose can increase to approximately 200 mg/dL (11.1 mmol/L) in patients without diabetes.</p><p class="headingAnchor" id="H4161484294"><span class="h2">Tremor, seizures, and other neurologic findings</span><span class="headingEndMark"> — </span>Common neurologic signs and symptoms include headache, tremor, weakness, anxiety, agitation, and dizziness. Delusions, hallucinations, and seizures can occur. Seizures tend to be severe, recurrent, and refractory to conventional treatment [<a href="#rid50">50</a>]<em>. </em>Muscular rigidity can cause rhabdomyolysis and kidney failure [<a href="#rid51">51</a>]<em>.</em></p><p class="headingAnchor" id="H2295704857"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Caffeine poisoning should be suspected in any patient with vomiting, tachycardia, hypokalemia, and hyperglycemia. Other ingestions and exposures that can present with similar symptoms include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta-adrenergic agonists</strong> – Agents such as <a class="drug drug_general" data-topicid="9396" href="/d/drug information/9396.html" rel="external">albuterol</a> (also known as salbutamol), clenbuterol, and <a class="drug drug_general" data-topicid="9977" href="/d/drug information/9977.html" rel="external">terbutaline</a> can cause similar symptoms, but seizures and cardiac dysrhythmias are rare [<a href="#rid52">52</a>]. Clenbuterol has been used as a performance-enhancing drug and as an adulterant in illicit opioids. Poisoning with these can only be differentiated by history of ingestion/use or caffeine concentration (if available). (See  <a class="medical medical_review" href="/d/html/15454.html" rel="external">"Prohibited non-hormonal performance-enhancing drugs in sport", section on 'Beta agonists'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Theophylline</strong><strong> and theobromine</strong> – These dimethylxanthines have toxicity similar to caffeine. Poisoning with these can only be differentiated by history of ingestion/use or caffeine/<a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> concentrations (if available). (See  <a class="medical medical_review" href="/d/html/6501.html" rel="external">"Theophylline poisoning"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cocaine, amphetamine, and cathinone</strong> – Cocaine, amphetamine, or synthetic cathinone intoxication can cause tremulousness, agitation, seizures, and tachydysrhythmias. Compared with caffeine poisoning, these agents are more likely to cause hypertension, diaphoresis, and hyperthermia and less likely to cause vomiting. (See  <a class="medical medical_review" href="/d/html/303.html" rel="external">"Cocaine: Acute intoxication", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/d/html/311.html" rel="external">"Methamphetamine: Acute intoxication", section on 'Examination findings associated with intoxication and complications'</a> and  <a class="medical medical_review" href="/d/html/82952.html" rel="external">"Acute amphetamine and synthetic cathinone ("bath salt") intoxication"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Iron</strong> – Vomiting is an early and consistent sign of iron poisoning, which can be accompanied by leukocytosis, hyperglycemia, metabolic acidosis, tachycardia, and hypotension. Compared with caffeine poisoning, vomiting is more likely to be bloody, and seizures are uncommon. Iron poisoning can be differentiated by obtaining a serum iron concentration. (See  <a class="medical medical_review" href="/d/html/6498.html" rel="external">"Acute iron poisoning"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Salicylates</strong> – Vomiting, tachycardia, hypotension, altered mental status, and seizures can occur with salicylate poisoning. However, salicylate poisoning typically causes a respiratory alkalosis with hyperpnea and can be differentiated by obtaining a serum salicylate concentration. (See  <a class="medical medical_review" href="/d/html/329.html" rel="external">"Salicylate (aspirin) poisoning: Clinical manifestations and evaluation"</a>.)</p><p></p><p class="headingAnchor" id="H3722772781"><span class="h1">EVALUATION AND DIAGNOSTIC TESTING</span></p><p class="headingAnchor" id="H1409266112"><span class="h2">History and examination</span><span class="headingEndMark"> — </span>In a patient with possible caffeine toxicity, we inquire regarding the details of the ingestion or caffeine use, such as the following:</p><p class="bulletIndent1"><span class="glyph">●</span>How much caffeine was ingested, including the formulation (eg, tablet, liquid, powder), concentration or dose per tablet, and amount? Was the ingestion intentional or accidental?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Does the patient have symptoms attributable to caffeine toxicity (eg, nausea, vomiting, headache, tremor, anxiety, agitation, restlessness)? (See <a class="local">'Clinical features of overdose'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the patient does not recall taking caffeine, could they have taken another source of caffeine such as beverages, energy drinks, over-the-counter (OTC) weight-loss or pre-workout supplements  (<a class="graphic graphic_table graphicRef139130" href="/d/graphic/139130.html" rel="external">table 2</a>), or combination analgesics? (See <a class="local">'Sources and toxic dose'</a> above.)</p><p></p><p>The physical examination helps determine the severity of toxicity and guides treatment. We assess for hemodynamic instability, seizure activity, altered mental status, signs of hypovolemia (eg, decreased turgor, cool extremities), tremor, restlessness, and anxiety.</p><p class="headingAnchor" id="H2193019737"><span class="h2">Laboratory and ancillary studies</span><span class="headingEndMark"> — </span>We obtain the following studies in a patient with suspected caffeine poisoning:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum caffeine<strong> </strong>concentration – Unless a hospital uses caffeine therapeutically (eg, to treat apnea of prematurity), a serum caffeine assay with rapid turnaround-time is typically unavailable (see <a class="local">'Caffeine in-house assay available'</a> below and <a class="local">'Caffeine in-house assay not available'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum electrolytes and glucose</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Electrocardiogram (ECG)</p><p></p><p>Additional studies may be indicated depending on the clinical situation:</p><p class="bulletIndent1"><span class="glyph">●</span>In a patient with hyperthermia or evidence of increased muscle tone: creatinine kinase and urinalysis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a patient with an intentional ingestion to rule out common co-ingestants: serum <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>, salicylate, and ethanol concentrations</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a female of childbearing age: urine pregnancy test</p><p></p><p class="headingAnchor" id="H2931228837"><span class="h3">Caffeine in-house assay available</span><span class="headingEndMark"> — </span>If the hospital laboratory performs a caffeine assay that results promptly, we obtain serum concentrations immediately and every one to two hours until there is a downward trend [<a href="#rid42">42</a>]. Serum caffeine concentrations generally correlate with clinical severity of intoxication.</p><p class="headingAnchor" id="H3558105067"><span class="h3">Caffeine in-house assay not available</span><span class="headingEndMark"> — </span>If the serum caffeine concentration will not result rapidly enough to guide evaluation and management, we obtain it if the result will be helpful for confirmatory or forensic purposes (eg, unclear if caffeine ingestion). Several analytical methods can quantify caffeine in biological samples, including gas chromatography, gas chromatography–mass spectrometry, high-performance liquid chromatography, and liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS), but these require sophisticated technology and are time consuming to perform [<a href="#rid23">23,43,53-56</a>]<em>.</em></p><p>The serum potassium concentration has been studied as a surrogate marker that inversely correlates with serum caffeine concentrations<em>.</em> A study of 85 patients with acute caffeine intoxication found that serum potassium concentrations &lt;3.3 mEq/L and &lt;2.9 mEq/L correlated with serum caffeine concentrations ≥20 mg/L (111 mmol/L) and ≥80 mg/L (444 mmol/L), respectively [<a href="#rid47">47</a>]<em>.</em></p><p class="headingAnchor" id="H2975093602"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of acute caffeine poisoning is suspected in a patient with concern for an ingestion or supratherapeutic use and characteristic findings (ie, vomiting, tremors, tachycardia, hypokalemia, hyperglycemia, seizures, tachydysrhythmia, and hypotension). The diagnosis is confirmed with an elevated serum caffeine concentration (&gt;20 mg/L [111 mmol/L]), if available, or with a compelling history of an ingestion (eg, suicide note, empty pill bottle) combined with characteristic findings.</p><p class="headingAnchor" id="H3460125433"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H1647546630"><span class="h2">ABCs and supportive care</span><span class="headingEndMark"> — </span>In a patient with concern for caffeine poisoning, initial management focuses on assessing and stabilizing airway, breathing, and circulation ("ABCs"). We obtain intravenous (IV) access and establish cardiac monitoring. Tracheal intubation and mechanical ventilation may be warranted in cases of severely impaired mentation or recurrent seizures. (See  <a class="medical medical_review" href="/d/html/13850.html" rel="external">"Initial management of the critically ill adult with an unknown overdose"</a>.)</p><p>Further management is mostly supportive and based on the patient's symptoms, signs, and hemodynamic findings. Intermittent hemodialysis and multiple-dose activated charcoal (MDAC) can effectively enhance elimination. Management is summarized in the rapid overview table  (<a class="graphic graphic_table graphicRef140994" href="/d/graphic/140994.html" rel="external">table 4</a>).</p><p class="headingAnchor" id="H3972227490"><span class="h2">Role of gastrointestinal decontamination</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Single-dose activated charcoal (AC)</strong> – In a patient who presents within two hours of a reported caffeine ingestion with preserved mental status and no emesis, we suggest administration of AC 50 g orally (1 g/kg to maximum dose 50 g). AC should not be given to a patient with depressed mental status without airway protection, but tracheal intubation should not be performed for the sole purpose of giving AC. The evidence for single-dose AC adsorbing organic compounds and limiting absorption is provided elsewhere. (See  <a class="medical medical_review" href="/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Activated charcoal'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Orogastric lavage</strong> – In the rare case that a patient presents within one hour of a reported large ingestion of caffeine powder or concentrated liquid and has preserved mental status and no emesis, we place a nasogastric tube for aspiration and lavage [<a href="#rid42">42</a>]<em>. </em>A standard (eg, 8 to 12 French) nasogastric tube is better tolerated and safer than traditional gastric lavage with a large-bore orogastric tube. The risks of orogastric lavage with a large-bore tube likely outweigh the benefits since caffeine is rapidly absorbed from the stomach (especially in powder or liquid form). (See  <a class="medical medical_review" href="/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Gastric lavage'</a>.)</p><p></p><p class="headingAnchor" id="H2822611101"><span class="h2">Management based on specific toxicity</span></p><p class="headingAnchor" id="H2250613562"><span class="h3">Dysrhythmias</span><span class="headingEndMark"> — </span>The presence of a life-threating dysrhythmia is an indication for hemodialysis. (See <a class="local">'Indications for extracorporeal removal'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supraventricular tachycardias (SVTs)</strong> – In a patient with caffeine-induced SVT (other than mild sinus tachycardia), we suggest administration of a benzodiazepine (eg, <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a>) or a beta-1-selective-adrenergic antagonist [<a href="#rid42">42</a>]<em>.</em> In a patient with a symptomatic, hemodynamically stable sinus tachycardia, a benzodiazepine (eg, lorazepam) is a reasonable option for first-line therapy. Benzodiazepines reduce central nervous system (CNS) catecholamine concentrations and potentially increase adenosine concentrations by inhibiting reuptake.</p><p></p><p class="bulletIndent1">In a patient with a severe sinus tachycardia (ie, heart rate &gt;150 beats per minute) or other SVT from caffeine toxicity, <a class="drug drug_general" data-topicid="9420" href="/d/drug information/9420.html" rel="external">esmolol</a> is a reasonable option for first-line therapy [<a href="#rid57">57</a>]<em>. </em>Both esmolol and <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a> are selective antagonists of the beta-1 adrenergic receptor and have minimal effect on beta-2 adrenergic receptors, thus preventing adverse effects such as exacerbation of reactive airway disease. Esmolol effects can be quickly titrated or turned off since it has the additional advantage of being ultra-short acting. Dosing is as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9420" href="/d/drug information/9420.html" rel="external">Esmolol</a>: Loading dose (optional) 500 mcg/kg over one minute; follow with a 50 mcg/kg/minute infusion for four minutes; infusion may be continued at 50 mcg/kg/minute or, if the response is inadequate, bolus (optional) 500 mcg/kg over one minute followed by titrating upward in 50 mcg/kg/minute increments (increased no more frequently than every four minutes) up to infusion rate of 300 mcg/kg/minute</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">Metoprolol</a>: 2.5 to 5mg IV repeated every 5 minutes; maximum dose 15 mg</p><p></p><p class="bulletIndent1">Beta-adrenergic antagonists decrease cardiac and peripheral beta-stimulation induced by caffeine. Many case reports have described the safe and successful use of beta-adrenergic antagonists for controlling caffeine-induced dysrhythmias [<a href="#rid21">21,44,57-59</a>]<em>.</em> However, patients in these reports often receive many different pharmacologic agents, thus complicating the ability to draw conclusions regarding any individual agent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ventricular dysrhythmias and other malignant rhythms (eg, SVT with hemodynamic instability) </strong>– These should be treated based on advanced cardiac life support or pediatric advanced life support guidelines. In a patient with a ventricular dysrhythmia, we administer a beta-adrenergic antagonist (eg, <a class="drug drug_general" data-topicid="9420" href="/d/drug information/9420.html" rel="external">esmolol</a> as described above)<strong> </strong>in addition to standard resuscitation measures. We consult nephrology early in the patient’s course to arrange for hemodialysis. (See  <a class="medical medical_review" href="/d/html/278.html" rel="external">"Advanced cardiac life support (ACLS) in adults", section on 'Management of specific arrhythmias'</a> and  <a class="medical medical_review" href="/d/html/6392.html" rel="external">"Pediatric advanced life support (PALS)", section on 'Heart rate and rhythm'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adenosine or electrical cardioversion unlikely to have sustained effect</strong> – In a patient with caffeine-induced SVT, administration of adenosine (which is a common treatment for other paroxysmal SVTs) will likely be ineffective or only provide a transient response [<a href="#rid59">59,60</a>]<em>.</em> Electrical cardioversion can be attempted for an SVT refractory to pharmacologic intervention but is unlikely to result in a sustained normal heart rhythm [<a href="#rid21">21</a>]. Defibrillation should be performed for a hemodynamically unstable dysrhythmia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extracorporeal membrane oxygenation as salvage option </strong>– In a patient with cardiovascular collapse that is refractory to conventional medical strategies, venoarterial<em> </em>extracorporeal membrane oxygenation (VA-ECMO) is a salvage option that can provide circulatory support while the intoxicant is cleared. In a case report, a patient with recurrent refractory ventricular fibrillation following a caffeine and <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a> overdose survived neurologically intact after treatment with VA-ECMO, which allowed time and circulatory support for correction of severe hypokalemia and for institution of hemodialysis to clear caffeine [<a href="#rid45">45</a>]<em>.</em> (See  <a class="medical medical_review" href="/d/html/1625.html" rel="external">"Extracorporeal life support in adults in the intensive care unit: Overview"</a>.)</p><p></p><p class="headingAnchor" id="H2202278651"><span class="h3">Seizure</span><span class="headingEndMark"> — </span>In a patient with caffeine-induced seizures, we administer benzodiazepines for first-line treatment. Repeated dosing may be required and should be titrated until clinical effect is achieved. Options include the following (see  <a class="medical medical_review" href="/d/html/96933.html" rel="external">"Convulsive status epilepticus in adults: Management", section on 'First therapy: Benzodiazepines'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">Lorazepam</a>: 4 mg IV (0.1 mg/kg IV; maximum 4 mg/dose), may repeat after three to five minutes</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">Diazepam</a>: 10 mg IV (0.15 to 0.2 mg/kg/dose IV; maximum 10 mg/dose), may repeat after three to five minutes; or 20 mg rectally (0.2 to 0.5 mg/kg rectally; maximum dose 20 mg/dose) once (preferred for rectal administration until IV access is obtained)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9650" href="/d/drug information/9650.html" rel="external">Midazolam</a>: 10 mg intramuscularly (IM; 0.2 mg/kg IM; maximum dose 10 mg) once (preferred for IM administration until IV access is obtained)</p><p></p><p>Caffeine-induced seizures may be severe and refractory to treatment. In a patient with persistent or recurrent seizures after two doses of a benzodiazepine, we administer a barbiturate (eg, <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9754" href="/d/drug information/9754.html" rel="external">pentobarbital</a>) or <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>. Tracheal intubation and close hemodynamic monitoring are typically required since these agents suppress respiratory drive and may exacerbate hypotension. Dosing is as follows (see  <a class="medical medical_review" href="/d/html/132561.html" rel="external">"Refractory status epilepticus in adults", section on 'Infusion therapies and other treatments'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">Phenobarbital</a>: 20 mg/kg IV (infused at 50 to 100 mg/minute); if necessary, may repeat once after 10 minutes with an additional 5 to 10 mg/kg</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">Propofol</a>: Loading dose 1 to 2 mg/kg followed by 0.5 to 2 mg/kg every three to five minutes until seizures are suppressed (maximum total dose 10 mg/kg), then followed by continuous infusion at an initial rate of 20 mcg/kg/minute</p><p></p><p>The presence of a seizure is an indication for hemodialysis. (See <a class="local">'Indications for extracorporeal removal'</a> below.)</p><p><a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">Phenytoin</a> and <a class="drug drug_general" data-topicid="8480" href="/d/drug information/8480.html" rel="external">fosphenytoin</a> are not beneficial and may be harmful in the treatment of caffeine-induced seizures. Phenytoin was found to increase mortality when administered to animals with methylxanthine toxicity [<a href="#rid61">61</a>]<em>.</em></p><p class="headingAnchor" id="H1025063104"><span class="h3">Hypotension</span><span class="headingEndMark"> — </span>Hypotension is initially treated with IV fluids, and therapy can be escalated to vasopressors or beta-adrenergic antagonists. The presence of persistent hypotension or shock is an indication for hemodialysis. (See <a class="local">'Indications for extracorporeal removal'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>IV fluids</strong> – In a patient with hypotension, we administer bolus volumes (10 to 20 mL/kg) of isotonic IV fluids (0.9% sodium chloride or <a class="drug drug_general" data-topicid="108196" href="/d/drug information/108196.html" rel="external">lactated Ringer</a> solution). If blood pressure does not adequately improve after three fluid boluses, we start a vasopressor and/or beta-adrenergic antagonist.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vasopressor therapy</strong> – In a patient with persistent hypotension despite IV fluids or with contraindications to repeated fluid boluses (eg, pulmonary edema), we initiate vasopressor therapy with <a class="drug drug_general" data-topicid="9768" href="/d/drug information/9768.html" rel="external">phenylephrine</a> or norepinephrine. Vasopressors with beta-adrenergic agonist effects (eg, epinephrine, <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a>, <a class="drug drug_general" data-topicid="8578" href="/d/drug information/8578.html" rel="external">isoproterenol</a>) should be avoided as they may worsen hypotension [<a href="#rid42">42</a>]<em>.</em> Dosing is as follows  (<a class="graphic graphic_table graphicRef99963" href="/d/graphic/99963.html" rel="external">table 5</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9768" href="/d/drug information/9768.html" rel="external">Phenylephrine</a> continuous IV infusion: Initial dose 40 to 160 mcg/minute (adults: 0.5 to 2 mcg/kg/minute; children: 0.1 to 0.5 mcg/kg/minute), titrate to effect</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Norepinephrine continuous IV infusion: Initial dose 5 to 15 mcg/minute (0.05 to 0.15 mcg/kg/minute), titrate to effect</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta-adrenergic antagonist</strong> – In a patient with refractory hypotension despite vasopressor therapy or as an alternative to vasopressor therapy, we suggest administering a beta-adrenergic antagonist (eg, <a class="drug drug_general" data-topicid="9420" href="/d/drug information/9420.html" rel="external">esmolol</a>, <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a>). Esmolol is the ideal agent since it has an ultra-short duration of action and its effects can easily be titrated or turned off if it does not produce the desired outcome.</p><p></p><p class="bulletIndent1">Although counterintuitive, a beta-adrenergic antagonist can actually increase blood pressure due to caffeine toxicity by inhibiting the beta-2-induced vasodilation and improve cardiac output by inhibiting the beta-1-induced tachycardia and increasing filling time. Evidence is limited to case reports, case series, and animal studies [<a href="#rid21">21,44,57,59,62,63</a>]. Beta-adrenergic antagonists are recommended for treatment of hypotension from other methylxanthines, such as <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a>. (See  <a class="medical medical_review" href="/d/html/6501.html" rel="external">"Theophylline poisoning", section on 'Hypotension'</a>.)</p><p></p><p class="bulletIndent1">The decision to use a beta-adrenergic antagonist to treat a hypotensive patient can be very difficult, and consultation with a medical toxicologist is often helpful. (See <a class="local">'Regional poison control centers'</a> below.)</p><p></p><p class="headingAnchor" id="H1863696271"><span class="h3">Vomiting</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9719" href="/d/drug information/9719.html" rel="external">Ondansetron</a> or <a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">metoclopramide</a>, often in large doses, may be required since caffeine-induced vomiting is frequently prolonged and severe. We ensure that the patient has a normal QTc interval prior to administering a 5-HT3 receptor antagonist (eg, ondansetron) or a dopamine receptor antagonist (eg, metoclopramide) given the association with QTc prolongation, especially in the presence of hypokalemia or hypomagnesemia [<a href="#rid64">64</a>]<em>. </em>The ondansetron initial dose is 0.15 mg/kg IV (maximum dose 16 mg). High doses of metoclopramide (up to 0.5 to 1 mg/kg; maximum dose 50 mg) may be necessary but have been associated with acute dystonic reactions, which can be treated with IV <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a>. Antiemetic drugs and potential adverse effects are discussed separately. (See  <a class="medical medical_review" href="/d/html/2538.html" rel="external">"Characteristics of antiemetic drugs"</a>.)</p><p><a class="drug drug_general" data-topicid="9265" href="/d/drug information/9265.html" rel="external">Cimetidine</a> is contraindicated as it may reduce clearance of caffeine due to inhibition of multiple CYP enzymes [<a href="#rid42">42</a>]<em>.</em></p><p class="headingAnchor" id="H1786152449"><span class="h3">Tremulousness, anxiety, restlessness</span><span class="headingEndMark"> — </span>We administer<strong> </strong>benzodiazepines (eg, <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a>, <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a>) for these CNS findings. In a patient with mild toxicity who is not vomiting, these can be administered orally; otherwise, these should be given IV. Doses are similar to those used for anxiety (eg, lorazepam 0.5 to 2mg; diazepam 2 to 5 mg).</p><p class="headingAnchor" id="H406114268"><span class="h3">Hypokalemia</span><span class="headingEndMark"> — </span>In a patient with caffeine-induced symptomatic hypokalemia, especially in the presence of muscle weakness, ventricular dysrhythmias, abnormal T waves, or prolonged QTc, we administer potassium supplementation [<a href="#rid42">42</a>]. Since hypokalemia is from potassium shift rather than potassium loss, lesser doses are needed compared with a patient with low total-body potassium. We administer 10 mEq/hour IV to most patients. There is no established serum potassium target, but a reasonable approach is to replete potassium until cardiac manifestations (eg, prolonged QTc) resolve. Details of potassium infusions are described in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2297.html" rel="external">"Clinical manifestations and treatment of hypokalemia in adults", section on 'Recommended approach'</a>.)</p><p>In a patient who remains symptomatic or is receiving potassium supplementation, we measure a serum potassium every two to four hours. (See  <a class="medical medical_review" href="/d/html/2297.html" rel="external">"Clinical manifestations and treatment of hypokalemia in adults", section on 'Careful monitoring'</a>.)</p><p>Asymptomatic hypokalemia (ie, no muscle weakness or ECG changes, except for sinus tachycardia) is generally well tolerated, and potassium supplementation is not needed. Aggressive correction of hypokalemia may cause hyperkalemia as toxicity resolves and potassium shifts out of the intracellular compartment.</p><p class="headingAnchor" id="H1319612426"><span class="h2">Role of elimination enhancement</span><span class="headingEndMark"> — </span>Caffeine elimination can be enhanced by MDAC or extracorporeal removal (ie, hemodialysis). In general, we use MDAC in a patient with moderate toxicity and hemodialysis in a patient with life-threatening toxicity.</p><p class="headingAnchor" id="H2342501319"><span class="h3">Multiple-dose activated charcoal</span><span class="headingEndMark"> — </span>In a patient with a caffeine overdose and anything beyond mild symptoms (eg, sinus tachycardia, restlessness), we suggest treatment with MDAC<em>.</em> The initial dose is 0.5 g/kg (maximum dose 50 g) AC followed by 0.5 g/kg (maximum dose 50 g) every four hours or 0.25 g/kg (maximum dose 25 g) every two hours of AC <strong>without </strong><a class="drug drug_general" data-topicid="9940" href="/d/drug information/9940.html" rel="external">sorbitol</a>.<strong> </strong>MDAC should be continued until the patient's clinical status is improving or the serum drug concentration (if available) is decreasing. MDAC may not be tolerated due to emesis. (See  <a class="medical medical_review" href="/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Multidose activated charcoal'</a>.)</p><p>We do not administer AC to a patient with altered mental status who may not be able to protect their airway, unless tracheal intubation is performed first. AC can be administered via orogastric tube to an intubated patient, but do not tracheally intubate solely for the purpose of administering AC.</p><p>Avoid an AC formulation combined with a cathartic (eg, <a class="drug drug_general" data-topicid="9940" href="/d/drug information/9940.html" rel="external">sorbitol</a>) because of potential for adverse effects such as vomiting and dehydration. It is reasonable to administer a combined formulation if a formulation of AC without a cathartic is unavailable, but limit treatment to a single dose in such cases.</p><p>Unlike single-dose AC (discussed above), MDAC can be started beyond two hours after ingestion because the mechanism of benefit is not just adsorbing caffeine in the gastrointestinal tract. MDAC increases elimination of caffeine by interrupting its enterohepatic recirculation [<a href="#rid42">42</a>]. The evidence for MDAC enhancing elimination of toxins that undergo enterohepatic recirculation is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Evidence of efficacy and adverse effects'</a>.)</p><p class="headingAnchor" id="H3226395391"><span class="h3">Indications for extracorporeal removal</span></p><p><strong>Intermittent hemodialysis</strong> —<strong> </strong>The following are indications for enhancing caffeine elimination with extracorporeal treatment (ECTR)  (<a class="graphic graphic_table graphicRef140995" href="/d/graphic/140995.html" rel="external">table 6</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Serum caffeine concentration (if available) &gt;100 mg/L (555 mmol/L) in acute exposure, &gt;60 mg/L (333 mmol/L) in chronic exposure</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of seizures</p><p class="bulletIndent1"><span class="glyph">●</span>Life-threatening dysrhythmias or shock</p><p class="bulletIndent1"><span class="glyph">●</span>Caffeine concentration (if available) that is rising despite MDAC</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical deterioration despite optimal therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Progressively worsening moderate to severe symptoms and inability to tolerate MDAC</p><p></p><p>Intermittent hemodialysis is the preferred choice of ECTR since it effectively and rapidly clears various toxins. The duration of a hemodialysis session is usually four to eight hours but should be governed by the clinical response and serum caffeine concentrations (if available). Cessation of ECTR is recommended when clinical improvement is apparent or the caffeine concentration is &lt;15 mg/L (83 micromol/L). Repeat treatment with ECTR may be needed if there is clinically significant redistribution (which is unlikely) or ongoing gastrointestinal absorption. (See  <a class="medical medical_review" href="/d/html/325.html" rel="external">"Enhanced elimination of poisons", section on 'Hemodialysis and hemoperfusion'</a>.)</p><p>We continue MDAC treatment (if tolerated) during ECTR. (See <a class="local">'Multiple-dose activated charcoal'</a> above.)</p><p>If hemodialysis is not available, alternative techniques to enhance elimination include hemoperfusion, continuous renal replacement therapy (CRRT), and exchange transfusion in neonates [<a href="#rid31">31,65</a>]. CRRT is better tolerated in hemodynamically unstable and/or hypotensive patients but has lower toxin clearance rates compared with conventional hemodialysis<em>.</em> (See  <a class="medical medical_review" href="/d/html/325.html" rel="external">"Enhanced elimination of poisons", section on 'Continuous renal replacement therapy (hemofiltration)'</a>.)</p><p>The evidence in support of ECTR to enhance caffeine elimination is based on its pharmacokinetic properties, its similarities with <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a>, and case reports. Caffeine is effectively cleared by hemodialysis because it has low protein binding (10 to 35 percent), small molecular mass (194 Daltons), and low volume of distribution (0.7 L/kg) [<a href="#rid31">31,32</a>]<em>.</em> Consensus guidelines developed for ECTR in theophylline poisoning can be extrapolated to caffeine poisoning since it is a structurally related methylxanthine with similar toxicity and pharmacokinetic properties [<a href="#rid32">32,42</a>]<em>.</em> (See  <a class="medical medical_review" href="/d/html/6501.html" rel="external">"Theophylline poisoning", section on 'Extracorporeal removal'</a>.)</p><p>In<em> </em>many case reports, patients with life-threatening toxicity (eg, ventricular dysrhythmias) after a caffeine overdose who were treated with hemodialysis had improved elimination and good clinical outcomes [<a href="#rid21">21,31,41,66,67</a>]<em>.</em><strong> </strong>In a patient with an initial serum caffeine concentration of 170 mg/L, the removal rate of caffeine with hemodialysis was 15.5 mg/L/hour, which is much higher than the approximate removal rate of 2 mg/L/hour in two patients not treated with hemodialysis (initial concentration 97 to 100 mg/L) [<a href="#rid21">21,68,69</a>].</p><p>The caffeine concentration thresholds for dialysis are extrapolated from <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> data. Following an acute ingestion, theophylline serum concentrations &gt;80 to 100 mg/L are likely to cause significant toxicity and death [<a href="#rid32">32</a>]. There are less robust data for caffeine. However, in two studies and a systematic review of caffeine fatalities, the majority of serum concentrations exceeded 100 mg/L, and almost all exceeded 80 mg/L, suggesting that 80 to 100 mg/L is a reasonable concentration threshold for hemodialysis [<a href="#rid2">2,23,70</a>]. Since no effective antidote for caffeine toxicity exists and initiating emergency dialysis takes time, if a caffeine concentration is available and potentially lethal, we would not delay consulting nephrology while waiting for life-threatening toxicity to develop.</p><p class="headingAnchor" id="H304747382"><span class="h1">DISPOSITION</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient being evaluated in an acute care facility</strong> – We admit to a critical care setting a patient who has any of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ongoing tachydysrhythmias</p><p class="bulletIndent2"><span class="glyph">•</span>Hypotension that does not resolve with intravenous (IV) fluids</p><p class="bulletIndent2"><span class="glyph">•</span>Seizures</p><p class="bulletIndent2"><span class="glyph">•</span>Hemodynamic instability</p><p class="bulletIndent2"><span class="glyph">•</span>Persistent vomiting</p><p class="bulletIndent2"><span class="glyph">•</span>Requiring extracorporeal removal</p><p class="bulletIndent2"><span class="glyph">•</span>Serum potassium &lt;2.9 mEq/L</p><p class="bulletIndent2"><span class="glyph">•</span>Serum caffeine concentration (if available) &gt;50 mg/L (278 mmol/L)</p><p></p><p class="bulletIndent1">In a patient who is symptomatic but does not meet the above criteria for critical care admission, we will observe (either in the emergency department or inpatient setting) until signs and symptoms have resolved.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient outside an acute care facility (eg, home)</strong> – We refer a patient with any of the following to an acute care facility (transfer via emergency medical services is strongly encouraged):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intentional ingestion (suicide or recreational)</p><p class="bulletIndent2"><span class="glyph">•</span>Any of the following symptoms: palpitations, agitation, seizure, nausea, vomiting</p><p class="bulletIndent2"><span class="glyph">•</span>Pediatric ingestions &gt;30 mg/kg</p><p class="bulletIndent2"><span class="glyph">•</span>Asymptomatic adult with an ingestion &gt;2 g or &gt;30 mg/kg</p><p></p><p class="bulletIndent1">In an asymptomatic child or adult with an unintentional ingestion &lt;30 mg/kg or &lt;2 g, respectively, we will recommend home observation. We will call back after two hours to assess for development of any symptoms since the concentration is expected to peak within two to three hours. We will refer to an acute care setting if the patient develops any of the above symptoms. </p><p></p><p class="headingAnchor" id="H3684765004"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H105237450"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p class="headingAnchor" id="H4259531955"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112689.html" rel="external">"Society guideline links: General measures for acute poisoning treatment"</a> and  <a class="medical medical_society_guidelines" href="/d/html/114014.html" rel="external">"Society guideline links: Treatment of acute poisoning caused by specific agents other than drugs of abuse"</a>.)</p><p class="headingAnchor" id="H1110705386"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sources and toxic dose</strong> – Caffeine is found in beverages, energy drinks, foods  (<a class="graphic graphic_table graphicRef79304" href="/d/graphic/79304.html" rel="external">table 1</a>), weight-loss and pre-workout supplements  (<a class="graphic graphic_table graphicRef139130" href="/d/graphic/139130.html" rel="external">table 2</a>), combination analgesics, and concentrated powders and liquids. Ingestion of &gt;150 to 200 mg/kg has a high risk of lethality, which tends to occur from concentrated caffeine products rather than beverages or foods. (See <a class="local">'Sources and toxic dose'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – The characteristic caffeine toxidrome includes vomiting, tachycardia, hypokalemia, and hyperglycemia. Toxicity is generally dose dependent, and at higher doses, agitation, seizures, ventricular dysrhythmias, hypotension, and shock can occur. (See <a class="local">'Clinical features of overdose'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and testing</strong> – We obtain the following studies: serum caffeine concentration, serum electrolytes and glucose, complete blood count, and electrocardiogram (ECG). (See <a class="local">'Laboratory and ancillary studies'</a> above.)</p><p></p><p class="bulletIndent1">If the hospital laboratory can perform a caffeine assay that results promptly, we obtain serum concentrations immediately and every one to two hours. (See <a class="local">'Caffeine in-house assay available'</a> above.)</p><p></p><p class="bulletIndent1">If the caffeine concentration will not result promptly, we obtain it for confirmatory or forensic purposes. The serum potassium concentration can be a surrogate marker that inversely correlates with caffeine concentrations. (See <a class="local">'Caffeine in-house assay not available'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of acute caffeine poisoning is suspected in a patient with concern for an ingestion or supratherapeutic use and characteristic findings (eg, vomiting, tremors, tachycardia, hypokalemia, hyperglycemia). The diagnosis is confirmed with an elevated serum caffeine concentration (&gt;20 mg/L [111 mmol/L]) or a compelling history of an ingestion combined with characteristic findings. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> <strong>by toxicity</strong> – A rapid overview table is provided to guide management  (<a class="graphic graphic_table graphicRef140994" href="/d/graphic/140994.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dysrhythmias</strong> – In a patient with caffeine-induced supraventricular tachycardia (SVT; other than mild sinus tachycardia), we suggest administration of a benzodiazepine or a beta-1-selective-adrenergic antagonist (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). In a patient with a symptomatic, hemodynamically stable sinus tachycardia, a benzodiazepine (eg, <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a>) is a reasonable option for first-line therapy. In a patient with a severe sinus tachycardia (ie, heart rate &gt;150 beats per minute) or other SVT, either <a class="drug drug_general" data-topicid="9420" href="/d/drug information/9420.html" rel="external">esmolol</a> or <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a> is an option, but esmolol has the advantage of being ultra-short acting. (See <a class="local">'Dysrhythmias'</a> above.)</p><p></p><p class="bulletIndent2">In a patient with a ventricular dysrhythmia, we suggest administration of a beta-adrenergic antagonist (eg, <a class="drug drug_general" data-topicid="9420" href="/d/drug information/9420.html" rel="external">esmolol</a>)<strong> </strong>in addition to standard resuscitation measures (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See  <a class="medical medical_review" href="/d/html/278.html" rel="external">"Advanced cardiac life support (ACLS) in adults", section on 'Management of specific arrhythmias'</a> and  <a class="medical medical_review" href="/d/html/6392.html" rel="external">"Pediatric advanced life support (PALS)", section on 'Heart rate and rhythm'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Seizure</strong> – We administer benzodiazepines (eg, <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a> 4 mg [0.1 mg/kg intravenously (IV); maximum 4 mg/dose]) for first-line treatment followed by a barbiturate (eg, <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>) or <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> for persistent or recurrent seizures. <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">Phenytoin</a> and <a class="drug drug_general" data-topicid="8480" href="/d/drug information/8480.html" rel="external">fosphenytoin</a> may be harmful. (See <a class="local">'Seizure'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypotension</strong> – We initially administer isotonic IV fluid boluses, escalating to vasopressor therapy as needed (eg, <a class="drug drug_general" data-topicid="9768" href="/d/drug information/9768.html" rel="external">phenylephrine</a>)  (<a class="graphic graphic_table graphicRef99963" href="/d/graphic/99963.html" rel="external">table 5</a>).</p><p></p><p class="bulletIndent2">In a patient with refractory hypotension or as an alternative to vasopressor therapy, we suggest administering a beta-adrenergic antagonist (eg, <a class="drug drug_general" data-topicid="9420" href="/d/drug information/9420.html" rel="external">esmolol</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Although counterintuitive, this can actually increase blood pressure by inhibiting the beta-2-induced vasodilation and beta-1-induced tachycardia. (See <a class="local">'Hypotension'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vomiting</strong> – <a class="drug drug_general" data-topicid="9719" href="/d/drug information/9719.html" rel="external">Ondansetron</a> (if normal QTc interval) or <a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">metoclopramide</a>, often in large doses, may be required. (See <a class="local">'Vomiting'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tremulousness, anxiety, and restlessness</strong> – We administer benzodiazepines (eg, <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a> 0.5 to 2 mg IV or orally). (See <a class="local">'Tremulousness, anxiety, restlessness'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypokalemia</strong> – We replete potassium only if hypokalemia is symptomatic (eg, muscle weakness, ventricular dysrhythmias, abnormal T waves, prolonged QTc interval). Aggressive correction of hypokalemia may cause hyperkalemia as toxicity resolves and potassium shifts out of the intracellular compartment. (See <a class="local">'Hypokalemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of gastrointestinal decontamination</strong> – In a patient who presents within two hours of a reported caffeine ingestion with preserved mental status and no emesis, we suggest administration of single-dose activated charcoal (AC) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The dose of AC is 50 g orally (1 g/kg to maximum dose 50 g). We lavage with a standard nasogastric tube if the patient is within one hour of a reported ingestion of concentrated powder or liquid but do not perform lavage with a large-bore orogastric tube. (See <a class="local">'Role of gastrointestinal decontamination'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of elimination enhancement</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Multiple-dose activated charcoal (MDAC)</strong> – In a patient with anything beyond mild symptoms (eg, sinus tachycardia, restlessness), we suggest treatment with MDAC (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>)<em>.</em> The initial dose is 0.5 g/kg (maximum dose 50 g) AC followed by 0.5 g/kg (maximum dose 50 g) every four hours or 0.25 g/kg (maximum dose 25 g) every two hours of AC <strong>without </strong><a class="drug drug_general" data-topicid="9940" href="/d/drug information/9940.html" rel="external">sorbitol</a>. (See <a class="local">'Multiple-dose activated charcoal'</a> above.)</p><p></p><p class="bulletIndent2">MDAC increases elimination by limiting enterohepatic recirculation; the evidence is discussed separately. (See  <a class="medical medical_review" href="/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Multidose activated charcoal'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Extracorporeal removal</strong> – In a patient with any of the following  (<a class="graphic graphic_table graphicRef140995" href="/d/graphic/140995.html" rel="external">table 6</a>), we recommend enhancing caffeine elimination with hemodialysis (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>) (see <a class="local">'Indications for extracorporeal removal'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Presence of seizures</p><p class="bulletIndent3"><span class="glyph">-</span>Life-threatening dysrhythmias or shock</p><p class="bulletIndent3"><span class="glyph">-</span>Clinical deterioration despite optimal therapy</p><p class="bulletIndent3"><span class="glyph">-</span>Progressively worsening moderate to severe symptoms and inability to tolerate MDAC</p><p class="bulletIndent3"><span class="glyph">-</span>Serum caffeine concentration (if available) &gt;100 mg/L (555 mmol/L) in acute exposure</p><p></p><p class="bulletIndent2">We also suggest hemodialysis for the following indications (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Serum caffeine concentration (if available) &gt;60 mg/L (333 mmol/L) in chronic exposure</p><p class="bulletIndent3"><span class="glyph">-</span>Caffeine concentration (if available) that is rising despite MDAC</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Banerjee P, Ali Z, Levine B, Fowler DR. Fatal caffeine intoxication: a series of eight cases from 1999 to 2009. J Forensic Sci 2014; 59:865.</a></li><li><a class="nounderline abstract_t">Cappelletti S, Piacentino D, Fineschi V, et al. Caffeine-Related Deaths: Manner of Deaths and Categories at Risk. Nutrients 2018; 10.</a></li><li><a class="nounderline abstract_t">Nawrot P, Jordan S, Eastwood J, et al. Effects of caffeine on human health. Food Addit Contam 2003; 20:1.</a></li><li><a class="nounderline abstract_t">Gummin DD, Mowry JB, Beuhler MC, et al. 2020 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 38th Annual Report. Clin Toxicol (Phila) 2021; 59:1282.</a></li><li><a class="nounderline abstract_t">Gummin DD, Mowry JB, Beuhler MC, et al. 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report. Clin Toxicol (Phila) 2020; 58:1360.</a></li><li><a class="nounderline abstract_t">Gummin DD, Mowry JB, Spyker DA, et al. 2018 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 36th Annual Report. Clin Toxicol (Phila) 2019; 57:1220.</a></li><li><a class="nounderline abstract_t">Gummin DD, Mowry JB, Spyker DA, et al. 2017 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 35th Annual Report. Clin Toxicol (Phila) 2018; 56:1213.</a></li><li><a class="nounderline abstract_t">Beauchamp GA, Johnson AR, Crouch BI, et al. A Retrospective Study of Clinical Effects of Powdered Caffeine Exposures Reported to Three US Poison Control Centers. J Med Toxicol 2016; 12:295.</a></li><li class="breakAll">Mattson ME. Update on emergency department visits involving energy drinks: A continuing public health concern. In: The CBHSQ Report, Substance Abuse and Mental Health Services Administration (US), Rockville, MD 2013.</li><li><a class="nounderline abstract_t">Sepkowitz KA. Energy drinks and caffeine-related adverse effects. JAMA 2013; 309:243.</a></li><li><a class="nounderline abstract_t">Berger AJ, Alford K. Cardiac arrest in a young man following excess consumption of caffeinated "energy drinks". Med J Aust 2009; 190:41.</a></li><li><a class="nounderline abstract_t">Rottlaender D, Motloch LJ, Reda S, et al. Cardiac arrest due to long QT syndrome associated with excessive consumption of energy drinks. Int J Cardiol 2012; 158:e51.</a></li><li><a class="nounderline abstract_t">Nordt SP, Vilke GM, Clark RF, et al. Energy drink use and adverse effects among emergency department patients. J Community Health 2012; 37:976.</a></li><li><a class="nounderline abstract_t">Fulgoni VL 3rd, Keast DR, Lieberman HR. Trends in intake and sources of caffeine in the diets of US adults: 2001-2010. Am J Clin Nutr 2015; 101:1081.</a></li><li><a class="nounderline abstract_t">Hampton T. FDA alert on pure caffeine powder. JAMA 2014; 312:779.</a></li><li><a class="nounderline abstract_t">Davies S, Lee T, Ramsey J, et al. Risk of caffeine toxicity associated with the use of 'legal highs' (novel psychoactive substances). Eur J Clin Pharmacol 2012; 68:435.</a></li><li><a class="nounderline abstract_t">Bioh G, Gallagher MM, Prasad U. Survival of a highly toxic dose of caffeine. BMJ Case Rep 2013; 2013.</a></li><li><a class="nounderline abstract_t">Rudolph T, Knudsen K. A case of fatal caffeine poisoning. Acta Anaesthesiol Scand 2010; 54:521.</a></li><li><a class="nounderline abstract_t">Jabbar SB, Hanly MG. Fatal caffeine overdose: a case report and review of literature. Am J Forensic Med Pathol 2013; 34:321.</a></li><li><a class="nounderline abstract_t">Kamijo Y, Takai M, Fujita Y, Usui K. A Retrospective Study on the Epidemiological and Clinical Features of Emergency Patients with Large or Massive Consumption of Caffeinated Supplements or Energy Drinks in Japan. Intern Med 2018; 57:2141.</a></li><li><a class="nounderline abstract_t">Ou HC, Deng JF, Yang CC, et al. A successful experience using labetalol and hemodialysis to treat near-fatal caffeine poisoning: A case report with toxicodynamics. Am J Emerg Med 2022; 55:224.e1.</a></li><li><a class="nounderline abstract_t">Tisdell R, et al. Caffeine poisoning in an adult survival with a serum concentration of 400 mg/L and need for adenosine agonist antidotes. Vet Hum Toxicol 1986; 28:492.</a></li><li><a class="nounderline abstract_t">Jones AW. Review of Caffeine-Related Fatalities along with Postmortem Blood Concentrations in 51 Poisoning Deaths. J Anal Toxicol 2017; 41:167.</a></li><li><a class="nounderline abstract_t">Willson C. The clinical toxicology of caffeine: A review and case study. Toxicol Rep 2018; 5:1140.</a></li><li><a class="nounderline abstract_t">Kattwinkel J. Neonatal apnea: pathogenesis and therapy. J Pediatr 1977; 90:342.</a></li><li><a class="nounderline abstract_t">Aranda JV, Gorman W, Bergsteinsson H, Gunn T. Efficacy of caffeine in treatment of apnea in the low-birth-weight infant. J Pediatr 1977; 90:467.</a></li><li><a class="nounderline abstract_t">Bradberry SM, Vale JA. Disturbances of potassium homeostasis in poisoning. J Toxicol Clin Toxicol 1995; 33:295.</a></li><li><a class="nounderline abstract_t">Blanchard J, Sawers SJ. The absolute bioavailability of caffeine in man. Eur J Clin Pharmacol 1983; 24:93.</a></li><li><a class="nounderline abstract_t">AXELROD J, REICHENTHAL J. The fate of caffeine in man and a method for its estimation in biological material. J Pharmacol Exp Ther 1953; 107:519.</a></li><li class="breakAll">Rall TW. The Methylxanthines. In: Goodman and Gilman's Pharmacological Basis of Therapeutics, 9th ed, Hardman J (Ed), McGraw-Hill, New York 1993. p.1663.</li><li><a class="nounderline abstract_t">Ishigaki S, Fukasawa H, Kinoshita-Katahashi N, et al. Caffeine intoxication successfully treated by hemoperfusion and hemodialysis. Intern Med 2014; 53:2745.</a></li><li><a class="nounderline abstract_t">Ghannoum M, Wiegand TJ, Liu KD, et al. Extracorporeal treatment for theophylline poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol (Phila) 2015; 53:215.</a></li><li><a class="nounderline abstract_t">Arnaud MJ. Pharmacokinetics and metabolism of natural methylxanthines in animal and man. Handb Exp Pharmacol 2011; :33.</a></li><li><a class="nounderline abstract_t">Gu L, Gonzalez FJ, Kalow W, Tang BK. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 1992; 2:73.</a></li><li><a class="nounderline abstract_t">Cornelis MC, El-Sohemy A, Kabagambe EK, Campos H. Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA 2006; 295:1135.</a></li><li><a class="nounderline abstract_t">Carrillo JA, Benitez J. CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine. Br J Clin Pharmacol 1996; 41:605.</a></li><li class="breakAll">Institute of Medicine (US) Committee on Military Nutrition Research. Caffeine for the Sustainment of Mental Task Performance: Formulations for Military Operations, National Academies Press (US), Washington, DC 2001.</li><li><a class="nounderline abstract_t">Poussel M, Kimmoun A, Levy B, et al. Fatal cardiac arrhythmia following voluntary caffeine overdose in an amateur body-builder athlete. Int J Cardiol 2013; 166:e41.</a></li><li><a class="nounderline abstract_t">Hanan Israelit S, Strizevsky A, Raviv B. ST elevation myocardial infarction in a young patientafter ingestion of caffeinated energy drink and ecstasy. World J Emerg Med 2012; 3:305.</a></li><li><a class="nounderline abstract_t">Fabrizio C, Desiderio M, Coyne RF. Electrocardiogram Abnormalities of Caffeine Overdose. Circ Arrhythm Electrophysiol 2016; 9.</a></li><li><a class="nounderline abstract_t">Laskowski LK, Henesch JA, Nelson LS, et al. Start me up! Recurrent ventricular tachydysrhythmias following intentional concentrated caffeine ingestion. Clin Toxicol (Phila) 2015; 53:830.</a></li><li class="breakAll">Hoffman RJ. Methylxanthines and selective β2-adrenergic agonists. In: Goldfrank's Toxicologic Emergencies, 11e, Nelson LS, Howland M, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS (Eds), McGraw Hill, 2019.</li><li><a class="nounderline abstract_t">Usui K, Fujita Y, Kamijo Y, et al. LC-MS/MS method for rapid and accurate detection of caffeine in a suspected overdose case. J Pharmacol Toxicol Methods 2021; 107:106946.</a></li><li><a class="nounderline abstract_t">Ajjampur K, Subramaniam A. The importance of early use of beta blockers and gastric decontamination in caffeine overdose: A case report. Aust Crit Care 2021; 34:395.</a></li><li><a class="nounderline abstract_t">Kato Y, Kuriyama A, Hata R, Ikegami T. Extracorporeal Membrane Oxygenation for Hypokalemia and Refractory Ventricular Fibrillation Associated with Caffeine Intoxication. J Emerg Med 2020; 58:59.</a></li><li><a class="nounderline abstract_t">Forman J, Aizer A, Young CR. Myocardial infarction resulting from caffeine overdose in an anorectic woman. Ann Emerg Med 1997; 29:178.</a></li><li><a class="nounderline abstract_t">Tsuji T, Morita S, Saito T, et al. Serum potassium level as a biomarker for acute caffeine poisoning. Acute Med Surg 2020; 7:e568.</a></li><li><a class="nounderline abstract_t">Tajima Y. Coffee-induced Hypokalaemia. Clin Med Insights Case Rep 2010; 3:9.</a></li><li><a class="nounderline abstract_t">Tsimihodimos V, Kakaidi V, Elisaf M. Cola-induced hypokalaemia: pathophysiological mechanisms and clinical implications. Int J Clin Pract 2009; 63:900.</a></li><li><a class="nounderline abstract_t">Eldridge FL, Paydarfar D, Scott SC, Dowell RT. Role of endogenous adenosine in recurrent generalized seizures. Exp Neurol 1989; 103:179.</a></li><li><a class="nounderline abstract_t">Chiang WF, Liao MT, Cheng CJ, Lin SH. Rhabdomyolysis induced by excessive coffee drinking. Hum Exp Toxicol 2014; 33:878.</a></li><li><a class="nounderline abstract_t">Wiley JF 2nd, Spiller HA, Krenzelok EP, Borys DJ. Unintentional albuterol ingestion in children. Pediatr Emerg Care 1994; 10:193.</a></li><li><a class="nounderline abstract_t">Brooks KE, Smith NB. Efficient extraction of basic, neutral, and weakly acidic drugs from plasma for analysis by gas chromatography-mass spectrometry. Clin Chem 1991; 37:1975.</a></li><li><a class="nounderline abstract_t">Chen F, Hu ZY, Parker RB, Laizure SC. Measurement of caffeine and its three primary metabolites in human plasma by HPLC-ESI-MS/MS and clinical application. Biomed Chromatogr 2017; 31.</a></li><li><a class="nounderline abstract_t">Lopez-Sanchez RDC, Lara-Diaz VJ, Aranda-Gutierrez A, et al. HPLC Method for Quantification of Caffeine and Its Three Major Metabolites in Human Plasma Using Fetal Bovine Serum Matrix to Evaluate Prenatal Drug Exposure. J Anal Methods Chem 2018; 2018:2085059.</a></li><li><a class="nounderline abstract_t">Koller D, Zubiaur P, Saiz-Rodríguez M, et al. Simultaneous determination of six antipsychotics, two of their metabolites and caffeine in human plasma by LC-MS/MS using a phospholipid-removal microelution-solid phase extraction method for sample preparation. Talanta 2019; 198:159.</a></li><li><a class="nounderline abstract_t">Price KR, Fligner DJ. Treatment of caffeine toxicity with esmolol. Ann Emerg Med 1990; 19:44.</a></li><li><a class="nounderline abstract_t">Strubelt O, Diederich KW. Experimental treatment of the acute cardiovascular toxicity of caffeine. J Toxicol Clin Toxicol 1999; 37:29.</a></li><li><a class="nounderline abstract_t">Li SF, Edwards L, Nguyen V. Treatment of caffeine toxicity with metoprolol. Am J Emerg Med 2019; 37:562.e5.</a></li><li><a class="nounderline abstract_t">Cabalag MS, Taylor DM, Knott JC, et al. Recent caffeine ingestion reduces adenosine efficacy in the treatment of paroxysmal supraventricular tachycardia. Acad Emerg Med 2010; 17:44.</a></li><li><a class="nounderline abstract_t">Blake KV, Massey KL, Hendeles L, et al. Relative efficacy of phenytoin and phenobarbital for the prevention of theophylline-induced seizures in mice. Ann Emerg Med 1988; 17:1024.</a></li><li><a class="nounderline abstract_t">Biberstein MP, Ziegler MG, Ward DM. Use of beta-blockade and hemoperfusion for acute theophylline poisoning. West J Med 1984; 141:485.</a></li><li><a class="nounderline abstract_t">Gaar GG, Banner W Jr, Laddu AR. The effects of esmolol on the hemodynamics of acute theophylline toxicity. Ann Emerg Med 1987; 16:1334.</a></li><li><a class="nounderline abstract_t">Charbit B, Alvarez JC, Dasque E, et al. Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study. Anesthesiology 2008; 109:206.</a></li><li><a class="nounderline abstract_t">Nojima T, Naito H, Kosaki Y, et al. Caffeine Intoxication in Pregnancy; a case Report. Arch Acad Emerg Med 2019; 7:e67.</a></li><li><a class="nounderline abstract_t">Kohl BA, Kaur K, Dincher N, et al. Acute intentional caffeine overdose treated preemptively with hemodialysis. Am J Emerg Med 2020; 38:692.e1.</a></li><li><a class="nounderline abstract_t">Fausch K, Uehlinger DE, Jakob S, Pasch A. Haemodialysis in massive caffeine intoxication. Clin Kidney J 2012; 5:150.</a></li><li><a class="nounderline abstract_t">Schmidt A, Karlson-Stiber C. Caffeine poisoning and lactate rise: an overlooked toxic effect? Acta Anaesthesiol Scand 2008; 52:1012.</a></li><li><a class="nounderline abstract_t">Adachi K, Beppu S, Terashima M, et al. Pharmacokinetics of caffeine self-administered in overdose in a Japanese patient admitted to hospital. J Pharm Health Care Sci 2021; 7:36.</a></li><li class="breakAll">Clarke's analysis of drugs and poisons in pharmaceuticals, body fluids, and postmortem material, third ed, Moffat AC, Osselton MD, Widdop B, Galichet LY (Eds), Pharmaceutical Press, London 2004. p.736.</li></ol></div><div id="topicVersionRevision">Topic 139562 Version 3.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24502704" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Fatal caffeine intoxication: a series of eight cases from 1999 to 2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29757951" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Caffeine-Related Deaths: Manner of Deaths and Categories at Risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12519715" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Effects of caffeine on human health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34890263" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : 2020 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 38th Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33305966" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31752545" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : 2018 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 36th Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30576252" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : 2017 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 35th Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27043735" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A Retrospective Study of Clinical Effects of Powdered Caffeine Exposures Reported to Three US Poison Control Centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27043735" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A Retrospective Study of Clinical Effects of Powdered Caffeine Exposures Reported to Three US Poison Control Centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23330171" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Energy drinks and caffeine-related adverse effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19120009" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cardiac arrest in a young man following excess consumption of caffeinated "energy drinks".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22056042" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cardiac arrest due to long QT syndrome associated with excessive consumption of energy drinks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22367607" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Energy drink use and adverse effects among emergency department patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25832334" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Trends in intake and sources of caffeine in the diets of US adults: 2001-2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : FDA alert on pure caffeine powder</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22037564" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Risk of caffeine toxicity associated with the use of 'legal highs' (novel psychoactive substances).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23396922" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Survival of a highly toxic dose of caffeine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20096021" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A case of fatal caffeine poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24196726" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Fatal caffeine overdose: a case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29526946" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A Retrospective Study on the Epidemiological and Clinical Features of Emergency Patients with Large or Massive Consumption of Caffeinated Supplements or Energy Drinks in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34922795" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A successful experience using labetalol and hemodialysis to treat near-fatal caffeine poisoning: A case report with toxicodynamics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Caffeine poisoning in an adult survival with a serum concentration of 400 mg/L and need for adenosine agonist antidotes</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28334840" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Review of Caffeine-Related Fatalities along with Postmortem Blood Concentrations in 51 Poisoning Deaths.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30505695" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The clinical toxicology of caffeine: A review and case study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/839325" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Neonatal apnea: pathogenesis and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14241" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Efficacy of caffeine in treatment of apnea in the low-birth-weight infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7629896" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Disturbances of potassium homeostasis in poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6832208" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The absolute bioavailability of caffeine in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13053413" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The fate of caffeine in man and a method for its estimation in biological material.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13053413" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The fate of caffeine in man and a method for its estimation in biological material.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25447662" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Caffeine intoxication successfully treated by hemoperfusion and hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25715736" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Extracorporeal treatment for theophylline poisoning: systematic review and recommendations from the EXTRIP workgroup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20859793" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pharmacokinetics and metabolism of natural methylxanthines in animal and man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1302044" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16522833" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Coffee, CYP1A2 genotype, and risk of myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8799528" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8799528" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23465232" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Fatal cardiac arrhythmia following voluntary caffeine overdose in an amateur body-builder athlete.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25215082" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : ST elevation myocardial infarction in a young patientafter ingestion of caffeinated energy drink and ecstasy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27406599" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Electrocardiogram Abnormalities of Caffeine Overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26279469" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Start me up! Recurrent ventricular tachydysrhythmias following intentional concentrated caffeine ingestion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26279469" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Start me up! Recurrent ventricular tachydysrhythmias following intentional concentrated caffeine ingestion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33276087" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : LC-MS/MS method for rapid and accurate detection of caffeine in a suspected overdose case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33131980" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The importance of early use of beta blockers and gastric decontamination in caffeine overdose: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31740156" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Extracorporeal Membrane Oxygenation for Hypokalemia and Refractory Ventricular Fibrillation Associated with Caffeine Intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8998103" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Myocardial infarction resulting from caffeine overdose in an anorectic woman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32995022" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Serum potassium level as a biomarker for acute caffeine poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21769248" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Coffee-induced Hypokalaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19490200" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Cola-induced hypokalaemia: pathophysiological mechanisms and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2912762" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Role of endogenous adenosine in recurrent generalized seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24220878" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Rhabdomyolysis induced by excessive coffee drinking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7937293" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Unintentional albuterol ingestion in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1934472" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Efficient extraction of basic, neutral, and weakly acidic drugs from plasma for analysis by gas chromatography-mass spectrometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27864843" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Measurement of caffeine and its three primary metabolites in human plasma by HPLC-ESI-MS/MS and clinical application.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30186659" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : HPLC Method for Quantification of Caffeine and Its Three Major Metabolites in Human Plasma Using Fetal Bovine Serum Matrix to Evaluate Prenatal Drug Exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30876545" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Simultaneous determination of six antipsychotics, two of their metabolites and caffeine in human plasma by LC-MS/MS using a phospholipid-removal microelution-solid phase extraction method for sample preparation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1688693" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Treatment of caffeine toxicity with esmolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10078157" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Experimental treatment of the acute cardiovascular toxicity of caffeine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30514596" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Treatment of caffeine toxicity with metoprolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20003123" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Recent caffeine ingestion reduces adenosine efficacy in the treatment of paroxysmal supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3177989" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Relative efficacy of phenytoin and phenobarbital for the prevention of theophylline-induced seizures in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6506685" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Use of beta-blockade and hemoperfusion for acute theophylline poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3688594" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The effects of esmolol on the hemodynamics of acute theophylline toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18648229" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32021978" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Caffeine Intoxication in Pregnancy; a case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31785982" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Acute intentional caffeine overdose treated preemptively with hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29497518" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Haemodialysis in massive caffeine intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18494847" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Caffeine poisoning and lactate rise: an overlooked toxic effect?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34602096" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Pharmacokinetics of caffeine self-administered in overdose in a Japanese patient admitted to hospital.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
